Amina Zoubeidi

Dr. Amina Zoubeidi is an assistant professor in the Department of Urologic Sciences, Faculty of Medicine at the University of British Columbia (UBC), and a scientist at the Vancouver Prostate Centre. She holds several awards including a Michael Smith Foundation for Health Research Scholar Award, Prostate Cancer Foundation New Investigator Award (USA), Terry Fox Research Institute New Investigator Award, Merit Award for academic achievement (UBC), and the American Association for Cancer Research – Brigid G. Leventhal Scholar Award, among others. Zoubeidi also holds operating grants from the Terry Fox Research Institute, Canadian Institute of Health Research, Prostate Cancer Canada, Prostate Cancer Foundation, and the National Cancer Institute.

Zoubeidi earned her PhD in biochemistry from University of Montreal with a focus on the role of tyrosine kinases in prostate cancer progression and pursued a post-doc at UBC. Her current research interest is to uncover molecular mechanisms of prostate cancer progression to the castrate-resistant stage and metastatic disease with a special interest on elucidating mechanisms of emergence of cancer stem cells and epithelial mesenchymal transition.

Recent Publications

Shiota M, Bishop JL, Nip K, Zardan A, Takeushi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi KN, Gleave M, Zoubeidi A. Hsp27 regulates epithelial mesenchymal transition, metastasis and circulating tumor cells in prostate cancer. Cancer Res. 2013 Mar 14. [Epub ahead of print] (PubMed abstract)

Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, Gleave ME, Zoubeidi A. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013 Feb 15;19(4):833-44. doi: 10.1158/1078-0432.CCR-12-3114. Epub 2012 Dec 20. (PubMed abstract)

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A. A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Mol Cancer Ther. 2013 Apr 26. [Epub ahead of print] (PubMed abstract)

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. (PubMed abstract)

Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56. doi: 10.1016/j.biocel.2012.04.010. Epub 2012 May 6. (PubMed abstract)